Results 221 to 230 of about 32,790 (255)

Topoisomerase I and II Inhibitors: A Patent Review

Recent Patents on Anti-Cancer Drug Discovery, 2016
Topoisomerases are a set of nuclear enzymes that play a vital role in handling of topological consequences of DNA during various genetic activities necessary for vitality of cell. Inhibition of these enzymes consequently leads to the blockage of ligation step of the cell cycle which generates single and double strand breakage in DNA strand ...
Arshdeep, Singh, Navdeep, Kaur, Gurpreet, Singh, Pooja, Sharma, Pms, Bedi, Sahil, Sharma, Kunal, Nepali   +6 more
openaire   +2 more sources

Targeting topoisomerase I: molecular mechanisms and cellular determinants of response to topoisomerase I inhibitors

Expert Opinion on Therapeutic Targets, 2008
Topoisomerase I is required for DNA relaxation during critical cellular functions. The identification of camptothecins as specific enzyme inhibitors and their clinical efficacy have stimulated extensive efforts to exploit topoisomerase I as a tumor target and explain the putative mechanisms of antitumor-specific action.This review provides an overview ...
Giovanni Luca, Beretta, Paola, Perego, Franco, Zunino   +2 more
openaire   +2 more sources

DNA Topoisomerase I Inhibitors from Rinorea anguifera.

ChemInform, 2005
AbstractFor Abstract see ChemInform Abstract in Full Text.
Ji, Ma, Shannon H, Jones, Rebekah, Marshall, Xihan, Wu, Sidney M, Hecht   +4 more
openaire   +2 more sources

Inhibitors of Topoisomerase I Function

2005
As noted elsewhere in this book, the locus of action of camptothecin (CPT) (1) (Fig. 1) as an antitumor agent involves the noncovalent binding of this agent to the covalent binary complex formed between topoisomerase I (TOP-I) and DNA (Fig. 2) (1). Although the equilibrium between free enzyme and the enzyme-DNA binary complex normally lies far toward ...
openaire   +1 more source

Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors.

Pharmacy world & science : PWS, 1998
In this review the clinical pharmacokinetics of camptothecin topoisomerase I inhibitors, an important new class of anticancer drugs, is discussed. Two prototypes, topotecan and irinotecan, are currently marketed in many European countries and the USA for the treatment of patients with ovarian and colorectal cancer, respectively.
Herben, V.M.M., ten Bokkel Huinink, W.W., Schellens, J.H.M., Beijnen, J.H.   +3 more
openaire   +2 more sources

[Molecular determinants of response to topoisomerase I inhibitors].

Bulletin du cancer, 2011
Nuclear topoisomerase I (Top1) is involved in the relaxation of DNA supercoiling and plays a pivotal role in the coordination of essential DNA processes such as transcription, replication, DNA recombination and DNA damage signalling. For all these reasons, Top1 has been an attractive target for the development of anticancer drugs, which poison Top1 by ...
Pourquier, Philippe, Lansiaux, Amélie
openaire   +4 more sources

Topoisomerase I inhibitors: topotecan and irenotecan

Cancer Treatment Reviews, 1994
G J, Creemers, B, Lund, J, Verweij
openaire   +2 more sources

A Mini Review of Novel Topoisomerase II Inhibitors as Future Anticancer Agents

International Journal of Molecular Sciences, 2023
Toluwase Hezekiah Fatoki
exaly  

A patent review of topoisomerase I inhibitors (2016–present)

Expert Opinion on Therapeutic Patents, 2021
Asier Selas, Endika Martin-Encinas, Maria Fuertes   +2 more
exaly  

Clinical trials with the topoisomerase I inhibitors.

Seminars in oncology, 1993
Topoisomerase I represents a unique new target that can be exploited for development of new antineoplastic agents. There are now two new topoisomerase I inhibitors that are in early clinical trials that have generated a tremendous amount of interest. Topotecan (SKF 104864-A) is a topoisomerase I inhibitor that has been explored in phase I trials using ...
H A, Burris, M L, Rothenberg, J G, Kuhn, D D, Von Hoff   +3 more
openaire   +1 more source